<DOC>
	<DOCNO>NCT00290277</DOCNO>
	<brief_summary>Human papillomavirus infection clearly recognize cause cervical cancer . Indeed , infection cervix certain oncogenic type HPV , clear , lead time cervical cancer woman . This study evaluate immunogenicity safety HPV vaccine female subject age 10 - 14 year Korea .</brief_summary>
	<brief_title>Evaluate Immunogenicity &amp; Safety GSK Biologicals ' HPV Vaccine Female Subjects Aged 10-14 Years</brief_title>
	<detailed_description>Study participant receive either HPV hepatitis A vaccine , study duration last 7 month involve total 4 visit .</detailed_description>
	<criteria>Inclusion criterion : A female subject , include , 10 14 year age time first vaccination . Written inform assent subject inform consent parent guardian subject obtain prior enrolment . Subjects must negative urine pregnancy test . Healthy subject enter study establish medical history clinical examination . Subject must nonchildbearing potential . Exclusion criterion : Pregnant breastfeeding . Previous vaccination HPV . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality History chronic condition ( ) require treatment cancer , chronic hepatic kidney disease ( ) , diabetes , autoimmune disease . ''</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>